Adherence to regular tablets ( median tablets consumed per participant per day of maximum 6 ; 40 [ IQR 16-57 ] in the regular group , 39 [ 15-56 ] in the as-needed group , and 40 [ 15-57 ] in the placebo group ) , and number of participants reporting adverse events ( 99 [ 185 % ] in the regular group , 99 [ 187 % ] in the as-needed group , and 98 [ 185 % ] in the placebo group ) were similar between groups .